Watson Pharmaceuticals

Apple (NASDAQ: AAPL) and Amazon.com (NASDAQ: AMZN) may have posted stellar results, but earnings season rolls on. Here is a quick day-by-day rundown of what analysts are expecting from some of this week's most prominent earnings reports. Monday Anadarko Petroleum (NYSE: APC) and Watson...

Halloween and the Day of the Dead arrive this week. If analysts' forecasts are correct, there are only a few earnings reports that may scare investors. For instance, Alpha Natural Resources (NYSE: ANR) earnings are predicted to have fallen 93.1% year over year to $0.58 per share. Allstate (NYSE:...

Watson Pharmaceuticals (NYSE: WPI) is scheduled to report its second-quarter 2011 results Tuesday, July 26, before the markets open. Strong first-quarter results pushed the share price to a new all-time high; can second-quarter results do the same? Analysts are looking for the drug maker to report...

According to Morgan Stanley, Watson Pharmaceuticals (NYSE: WPI) price target is raised to $78. Morgan Stanley said that it raised its ‘11E EPS 5% from $4.13 to $4.34 and its ‘12E EPS 10% from $5.21 to $5.74. “Our ‘11E-‘12E are 3% and 6% above cons' $4.23 and $5.42. We expect WPI to raise 2011...

Morgan Stanley has raised the price target on Watson Pharmaceuticals (NYSE: WPI) from $68 to $78 and maintains its Overweight rating.

Forest Laboratories (NYSE: FRX) and Watson Pharmaceuticals (NYSE: WPI) reached new 52-week highs of $40.52 and $66.00 per share, respectively, in Wednesday's trading session. Forest Labs saw an upgrade from Argus and Duncan-Williams upgraded its price target on the stock to $45 in the wake of...

Piper Jaffray is out with its report today on Watson Pharmaceuticals (NYSE: WPI), raising its PT from $72 to $76. In a note to clients, Piper Jaffray writes, "With a P/E of only 11x our new 2012 EPS estimate of $5.94 (up from $5.69), and significant potential for double-digit EPS growth beyond...

Piper Jaffray has raised the price target on Watson Pharmaceuticals (NYSE: WPI) from $72 to $76 and maintains its Overweight rating.

Credit Suisse made a number of estimates and price target changes in a research report published today. BG Group plc (BRGYY) had its price target cut to 1,690p from 1,710p. At the moment, Credit Suisse has an outperform rating on the company's stock. In the report Credit Suisse states, "In this...

Citi reiterated its Buy rating on Watson Pharmaceuticals (NYSE: WPI). At the same time, Citi raised its price target on the stock from $66 to $72. In a research report published today, Citi stressed it feels confident Watson's acquisition of Specifar Pharma will create additional value for the...

Piper Jaffray reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI). At the same time, Piper Jaffray left its price target unchanged at $72. In a research report published today, Piper cited the company's strong performance in the generic drugs market as the reason for its decision...

Piper Jaffray, which raised its PT on shares of Watson Pharmaceuticals Inc. (NYSE: WPI), is providing some color on the stock. “Watson's 1Q11 results were solid, with generics continuing to outperform, particularly on gross margins, coming in at 52% (versus 47% in 1Q10),” Piper Jaffray writes. “...

Piper Jaffray has raised the price target on Watson Pharmaceuticals (NYSE: WPI) from $62 to $72 and maintains its Overweight rating.

Citi is out with its report today on Watson Pharmaceuticals (NYSE: WPI), reiterating Buy. In a note to clients, Citi writes, "WPI expects to launch Nulecit (a generic of SNY's Ferrlecit for treating iron deficiency anemia in chronic dialysis patients) in a few weeks following GeneraMedix's ANDA...

Citi has reiterated the Buy Rating on Watson Pharmaceuticals, Inc. (NYSE: WPI). According to Citi, "Conclusion–WPI received final approval & shipped famciclovir, a generic version of NVS' Famvir, an oral antiviral used to treat herpes. This immediately followed expiration of pediatric...